echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Study of Nervous System > Front Immunol: Maf1 improves the occurrence of sepsis-related encephalopathy by inhibiting the NF-kB/NLRP3 inflammasome signaling pathway

    Front Immunol: Maf1 improves the occurrence of sepsis-related encephalopathy by inhibiting the NF-kB/NLRP3 inflammasome signaling pathway

    • Last Update: 2021-08-03
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    NOD-, LRR- and pyridine domain-containing protein 3 (NLRP3) inflammasomes have been identified as important mediators of blood-brain barrier destruction in sepsis-related encephalopathy (SAE)
    .
    However, there is currently no information on key upstream regulators of SAE


    .


     

    Researchers used lipopolysaccharide (LPS) to establish an in vitro model of blood-brain barrier (BBB) ​​destruction and an in vivo model of SAE
    .
    The destruction of BBB integrity was assessed by measuring the expression level of tight junction proteins


    .


    The results showed that Maf1 significantly inhibited LPS-induced brain inflammation and nerve apoptosis in vivo and in vitro
    .
    It is worth noting that Maf1 reduced the activation of NLRP3 inflammasome and the expression of pro-inflammatory cytokines induced by NF-κB/p65


    .


    In summary, the results of this study indicate that regulating Maf1 may be a treatment strategy for SAE and other inflammation-related neurodegenerative diseases


     

    Original source:

     

    Shenglong Chen, et al.


    Maf1 Ameliorates Sepsis-Associated Encephalopathy by Suppressing the NF- k B / NLRP3 Inflammasome Signaling Pathway In this message
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.